Infectious Diseases Research

Below are current clinical trials.

267 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. Will Making the HPV Vaccine Available at Mayo Clinic Express Care with Use of Electronic Point of Care Reminder Improve Overall Vaccination Rates Among an Empaneled Adolescent Population?

   Rochester, Minn.

   The purpose of this study is to determine if a medical record prompt at the time of a medical consult will help to address lapses in routine immunizations, including the HPV vaccine.

    

    

2. Prevalence and Predictors of Spike Protein Antibodies in COVID-19 Vaccinated Individuals

   Jacksonville, Fla.

   The objectives of this study are to determine the prevalence of spike (S) protein antibodies in COVID-19 vaccinated individuals, to assess the role of age and gender in relation to the capacity of COVID-19 vaccinated individuals to develop S protein antibodies, and to identify microRNA (miRNA) in serum derived exosomes that correlates with S protein antibody development and determine how age and gender may affect the correlation B.

3. A Study of Blood Mononuclear Cells from HIV Patients and Control Subjects

   Rochester, Minn.

   The purpose of this study is to provide the lab with a source of human PBMCs and serum from normal and HIV-1-infected individuals. We wish to analyze cells from HIV-infected and non-HIV infected individuals for levels of various proteins and mRNAs that are relevant to HIV research.

4. A Study to Establish a Registry of Post-COVID Investigations, Education and Symptom Management

   Rochester, Minn.

   The purpose of this study is to establish a registry that will follow patients that are seen in the PCCOC clinic with Post-COVID symptoms that persist for greater than 28 days. 

5. A Study to Evaluate Acalabrutinib with Best Supportive Care in Participants Hospitalized with COVID-19 (Enrolling by Invitation Only)

   Rochester, Minn.

   The purpose of this study is to evaluate the safety and tolerability of Acalabrutinib suspension when delivered via a nasogastric tube and co-administered with a Proton Pump Inhibitor, in the treatment of COVID-19.

6. A Study to Evaluate Convalescent Plasma to Stem Coronavirus

   Scottsdale/Phoenix, Ariz.

   
   The purpose of this study is to assess the effectiveness and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.

7. Research to Test Whether Doing Exercise Training Helps Lessen or Prevent the Longer-term Symptoms of COVID-19 Infection

   Jacksonville, Fla.

   The objectives of this study are to assess the ‘longer-term’ clinical, pulmonary, cardiac, functional, and psychosocial sequelae of COVID-19 survivorship, and to investigate whether exercise therapy enhances recovery of and/or improves pulmonary and cardiac function, exercise capacity, clinical status, and overall HRQoL in COVID-19 survivors.

    

    

8. A Study to Evaluate COVID19 Pregnancy Risks

   Rochester, Minn.

   It is unclear if and how COVID19 can be passed from mother to child. Therefore, we aim to collect maternal and fetal samples from COVID19-infected pregnant women and compare them to pregnant women who have clinical indications for COVID 19 testing at the time of hospital admission but end up being COVID19- (control group). Pregnant women who are either COVID19+ or COVID19- with symptoms will be followed during this study. Our objective is to understand the prevalence of maternal fetal transmission, risk factors and outcomes of a COVID19+ pregnancy, and how the virus can be passed from mother to baby in the population of Mayo Clinic patients. 

9. Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

   Scottsdale/Phoenix, Ariz.

   This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated interferon and RBV. The primary study hypothesis is that in at least one of the study arms, the percentage of participants achieving sustained viral response 12 weeks after the end of all study treatment (SVR12) will be superior to 58%.

10. Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis

    Rochester, Minn.

    The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo.